These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 22122271)
1. A case report of voriconazole therapy failure in a homozygous ultrarapid CYP2C19*17/*17 patient comedicated with carbamazepine. Malingré MM; Godschalk PC; Klein SK Br J Clin Pharmacol; 2012 Jul; 74(1):205-6. PubMed ID: 22122271 [No Abstract] [Full Text] [Related]
2. Clinical importance of the CYP2C19*17 variant allele for voriconazole. Dolton MJ; McLachlan AJ Br J Clin Pharmacol; 2011 Jan; 71(1):137-8. PubMed ID: 21143511 [No Abstract] [Full Text] [Related]
10. Safety of voriconazole in a patient with CYP2C9*2/CYP2C9*2 genotype. Geist MJ; Egerer G; Burhenne J; Mikus G Antimicrob Agents Chemother; 2006 Sep; 50(9):3227-8. PubMed ID: 16940139 [No Abstract] [Full Text] [Related]
11. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. Park WB; Kim NH; Kim KH; Lee SH; Nam WS; Yoon SH; Song KH; Choe PG; Kim NJ; Jang IJ; Oh MD; Yu KS Clin Infect Dis; 2012 Oct; 55(8):1080-7. PubMed ID: 22761409 [TBL] [Abstract][Full Text] [Related]
12. Voriconazole therapeutic drug monitoring: focus on safety. Pasqualotto AC; Xavier MO; Andreolla HF; Linden R Expert Opin Drug Saf; 2010 Jan; 9(1):125-37. PubMed ID: 20021293 [TBL] [Abstract][Full Text] [Related]
13. Inherited long QT syndrome revealed by antifungals drug-drug interaction. Eiden C; Peyrière H; Tichit R; Cociglio M; Amedro P; Blayac JP; Margueritte G; Hillaire-Buys D J Clin Pharm Ther; 2007 Jun; 32(3):321-4. PubMed ID: 17489884 [TBL] [Abstract][Full Text] [Related]
14. Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients. Kim SH; Yim DS; Choi SM; Kwon JC; Han S; Lee DG; Park C; Kwon EY; Park SH; Choi JH; Yoo JH Int J Infect Dis; 2011 Nov; 15(11):e753-8. PubMed ID: 21831685 [TBL] [Abstract][Full Text] [Related]
15. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir. Mikus G; Schöwel V; Drzewinska M; Rengelshausen J; Ding R; Riedel KD; Burhenne J; Weiss J; Thomsen T; Haefeli WE Clin Pharmacol Ther; 2006 Aug; 80(2):126-35. PubMed ID: 16890574 [TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetics and beyond: variability of voriconazole plasma levels in a patient with primary immunodeficiency. Autmizguine J; Krajinovic M; Rousseau J; Théorêt Y; Litalien C; Marquis C; Tapiéro B; Ovetchkine P Pharmacogenomics; 2012 Dec; 13(16):1961-5. PubMed ID: 23215888 [TBL] [Abstract][Full Text] [Related]
17. Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients. Berge M; Guillemain R; Trégouet DA; Amrein C; Boussaud V; Chevalier P; Lillo-Lelouet A; Le Beller C; Laurent-Puig P; Beaune PH; Billaud EM; Loriot MA Eur J Clin Pharmacol; 2011 Mar; 67(3):253-60. PubMed ID: 21038076 [TBL] [Abstract][Full Text] [Related]
18. Voriconazole toxicity related to polymorphisms in CYP2C19. Suan D; O'Connor K; Booth DR; Liddle C; Stewart GJ Intern Med J; 2011 Apr; 41(4):364-5. PubMed ID: 21507170 [No Abstract] [Full Text] [Related]
19. Correlation of CYP2C19 phenotype with voriconazole plasma concentration in children. Narita A; Muramatsu H; Sakaguchi H; Doisaki S; Tanaka M; Hama A; Shimada A; Takahashi Y; Yoshida N; Matsumoto K; Kato K; Kudo K; Furukawa-Hibi Y; Yamada K; Kojima S J Pediatr Hematol Oncol; 2013 Jul; 35(5):e219-23. PubMed ID: 23588332 [TBL] [Abstract][Full Text] [Related]
20. Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes. Murayama N; Imai N; Nakane T; Shimizu M; Yamazaki H Biochem Pharmacol; 2007 Jun; 73(12):2020-6. PubMed ID: 17433262 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]